648 related articles for article (PubMed ID: 9442783)
1. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation.
Rosenberg LF; Krupin T; Tang LQ; Hong PH; Ruderman JM
Ophthalmology; 1998 Jan; 105(1):88-92; discussion 92-3. PubMed ID: 9442783
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the efficacy and tolerability of dorzolamide and acetazolamide as adjunctive therapy to timolol. Oral to Topical CAI Study Group.
Hutzelmann JE; Polis AB; Michael AJ; Adamsons IA
Acta Ophthalmol Scand; 1998 Dec; 76(6):717-22. PubMed ID: 9881560
[TBL] [Abstract][Full Text] [Related]
3. Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma.
Portellos M; Buckley EG; Freedman SF
J AAPOS; 1998 Feb; 2(1):43-7. PubMed ID: 10532366
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and efficacy of dorzolamide versus acetazolamide added to timolol.
Stewart WC; Halper LK; Johnson-Pratt L; Polis A; Hartenbaum D
J Ocul Pharmacol Ther; 2002 Jun; 18(3):211-20. PubMed ID: 12099542
[TBL] [Abstract][Full Text] [Related]
5. Additive effect of dorzolamide on aqueous humor flow in patients receiving long-term treatment with timolol.
Wayman LL; Larsson LI; Maus TL; Brubaker RF
Arch Ophthalmol; 1998 Nov; 116(11):1438-40. PubMed ID: 9823342
[TBL] [Abstract][Full Text] [Related]
6. Changes in intraocular pressure associated with topical dorzolamide and oral methazolamide in glaucomatous dogs.
Gelatt KN; MacKay EO
Vet Ophthalmol; 2001 Mar; 4(1):61-7. PubMed ID: 11397321
[TBL] [Abstract][Full Text] [Related]
7. Topical 2.0% dorzolamide vs oral acetazolamide for prevention of intraocular pressure rise after neodymium:YAG laser posterior capsulotomy.
Ladas ID; Baltatzis S; Panagiotidis D; Zafirakis P; Kokolakis SN; Theodossiadis GP
Arch Ophthalmol; 1997 Oct; 115(10):1241-4. PubMed ID: 9338667
[TBL] [Abstract][Full Text] [Related]
8. Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide.
Larsson LI; Alm A
Arch Ophthalmol; 1998 Jan; 116(1):19-24. PubMed ID: 9445204
[TBL] [Abstract][Full Text] [Related]
9. Effects on aqueous flow of dorzolamide combined with either timolol or acetazolamide.
Toris CB; Zhan GL; Yablonski ME; Camras CB
J Glaucoma; 2004 Jun; 13(3):210-5. PubMed ID: 15118464
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans.
Maus TL; Larsson LI; McLaren JW; Brubaker RF
Arch Ophthalmol; 1997 Jan; 115(1):45-9. PubMed ID: 9006424
[TBL] [Abstract][Full Text] [Related]
11. The additive effect of topical dorzolamide and systemic acetazolamide in pediatric glaucoma.
Sabri K; Levin AV
J AAPOS; 2006 Oct; 10(5):464-8. PubMed ID: 17070484
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group.
Boyle JE; Ghosh K; Gieser DK; Adamsons IA
Ophthalmology; 1998 Oct; 105(10):1945-51. PubMed ID: 9787368
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
Boyle JE; Ghosh K; Gieser DK; Adamsons IA
Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group.
Strohmaier K; Snyder E; DuBiner H; Adamsons I
Ophthalmology; 1998 Oct; 105(10):1936-44. PubMed ID: 9787367
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological profiles of the potent carbonic anhydrase inhibitor dorzolamide hydrochloride, a topical antiglaucoma agent].
Kobayashi M; Naito K
Nihon Yakurigaku Zasshi; 2000 Jun; 115(6):323-8. PubMed ID: 10948564
[TBL] [Abstract][Full Text] [Related]
16. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure.
Kimal Arici M; Topalkara A; Güler C
Int Ophthalmol; 1998; 22(1):37-42. PubMed ID: 10090447
[TBL] [Abstract][Full Text] [Related]
17. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor.
Wilkerson M; Cyrlin M; Lippa EA; Esposito D; Deasy D; Panebianco D; Fazio R; Yablonski M; Shields MB
Arch Ophthalmol; 1993 Oct; 111(10):1343-50. PubMed ID: 8216014
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components.
Strohmaier K; Snyder E; DuBiner H; Adamsons I
Ophthalmology; 1999 Dec; 106(12 Suppl):1-9. PubMed ID: 10598691
[TBL] [Abstract][Full Text] [Related]
19. Effects of topical application of a 2% solution of dorzolamide on intraocular pressure and aqueous humor flow rate in clinically normal dogs.
Cawrse MA; Ward DA; Hendrix DV
Am J Vet Res; 2001 Jun; 62(6):859-63. PubMed ID: 11400841
[TBL] [Abstract][Full Text] [Related]
20. A topical or oral carbonic anhydrase inhibitor to control ocular hypertension after cataract surgery.
Abbasoğlu E; Tekeli O; Celikdoğan A; Gürsel E
Eur J Ophthalmol; 2000; 10(1):27-31. PubMed ID: 10744202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
